Overview
e184 is a venture capital firm that invests across multiple stages in HealthTech, FinTech, and SaaS in the United States, providing capital to startups and emerging companies to help them grow. It uses an equity-based venture model, funding early to late-stage companies and aiming to generate returns through exits like IPOs or acquisitions, with leadership coordinating capital allocation and leveraging expertise in payments, banking, crypto, and investments. The firm differentiates itself through its sector focus combined with flexible investment stages and a willingness to explore additional verticals, guided by deep knowledge of payments and financial technology. Its goal is to deliver high-growth returns for investors by funding innovative startups, helping them scale, and exiting positions profitably while continually pursuing new opportunities across industries.
Work here?Claim your company
Simplify's take
What believers are saying
- Paterna Biosciences raised a May 2026 Series A after e184 backed its seed round.
- e184 posted 2026 hiring for reproductive tech and BCI specialists, showing active execution.
- Its November 2026 website and June 2026 content signal continuing productization, not dormant storytelling.
What critics are saying
- The company abandoned its 2024 VC identity, signaling strategic drift and investor confusion in 2026.
- IVG, ectogenesis, and genome editing face FDA, bioethics, and clinical timelines extending beyond 2030.
- If any core program fails, e184 loses its entire thesis and becomes an expensive science project.
What makes e184 unique
- e184 combines reproduction, genome engineering, and non-invasive BCI under one 2026 biology platform.
- Its June 2026 Foresight partnership gave it unusual reach in frontier bioethics communities.
- Founder Kirill Eves backs long-horizon R&D, insulating scientific programs from near-term fundraising pressure.
Help us improve and share your feedback! Did you find this helpful?